Vbi Vaccines Inc's ROA from the first quarter of 2024 to the first quarter of 2023 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Vbi Vaccines Inc's ROA in the first quarter of 2024?
Vbi Vaccines Inc recorded a cumulative net loss of $-84 million during 12 months ending in the first quarter of 2024, resulting in a negative return on assets (ROA) of -124.25%.

However, within the Healthcare sector 845 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Mar 31 2024 quarter, so far to 4701, from total ROA ranking in the fourth quarter of 2023 at 5429.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Mar 31 2024) I. Quarter	(Dec 31 2023) IV. Quarter	(Sep 30 2023) III. Quarter	(Jun 30 2023) II. Quarter	(Mar 31 2023) I. Quarter
Y / Y Total Assets Change	4.96 %	-45.83 %	-12.25 %	-61.26 %	-49.53 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-84	-94	-115	-119	-120
Return On Assets (TTM)	-124.25 %	-140.45 %	-140.7 %	-139.87 %	-118.75 %
VBIV's Total Ranking	# 4701	# 5429	# 4911	# 4942	# 5011
Total Assets (TTM) in million	66	70	94	40	63
Seq. Total Assets Change	-5.33 %	-25.31 %	131.53 %	-35.88 %	-51.14 %
Seq. Net Income Change	-	-	-	-	-

VBIV's 5 Years Annual ROA >> Back to VBIV Management Effectiveness >> Compare VBIV ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 393
Sector	# 846
Overall	# 4618

Return On Assets Statistics
High	Average	Low
28.41 %	-56.92 %	-240.16 %
(Sep 30 2014)		(Sep 30 2015)

Financial Statements
Vbi Vaccines Inc's Assets	$ 66 million	VBIV's Balance sheet
Vbi Vaccines Inc's Income	$ -18 million	Quarterly VBIV's Income Statement
VBIV's Income by Division		See VBIV's Income by Division

Annual Return On Assets	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021	(Dec 31 2020) FY 2020	(Dec 31 2019) FY 2019
Y / Y Total Assets Change	-45.83 %	5.55 %	-0.38 %	237.58 %	-68.43 %
Total Assets in million	70	129	122	123	36
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-94	-113	-70	-46	-55
Annual Return On Assets	-134.1 %	-87.71 %	-56.99 %	-37.63 %	-150.62 %

VBIV's 5 Years Annual ROA >> Back to VBIV Management Effectiveness >> Compare VBIV ROA to its Competitors

More Return On Assets Ratios
VBIV's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
VBIV's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for VBIV's Competitors
Subscribers only: Roa for Vbi Vaccines Inc's Suppliers
Subscribers only: Return On Assets for VBIV's Customers

You may also want to know
VBIV's Roi	VBIV's Inventory Turnover Ratio	VBIV's Growth Rates	VBIV's Dividend Comparisons
	VBIV's Profitability Ratios	VBIV's Asset Turnover Ratio	VBIV's Dividend Growth
VBIV's Roe	VBIV's Valuation Ratios	VBIV's Financial Strength Ratios	VBIV's Dividend Payout Ratio

Companies with similar Return On Assets at Mar 31 2024, within Healthcare Sector

ROA

Date modified: 2026-09-26T07:31:35+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.